Innovation Pharmaceuticals Inc.
Innovation Pharmaceuticals Inc. (IPIX) Revenue
Annual & quarterly revenue history · segment & region breakdown
IPIX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsInnovation Pharmaceuticals Inc. trailing twelve-month (TTM) revenue is $-0.00B, a decrease of 100.00% year-over-year from $0.00B in FY2023.
Revenue trend
2023 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-06-30 | $0.00B | -$0.00B | -100.00% |
| 2022-06-30 | $0.00B | +$0.00B | — |
| 2021-06-30 | $0.00B | -$0.00B | -100.00% |
| 2020-06-30 | $0.00B | +$0.00B | — |
| 2019-06-30 | $0.00B | +$0.00B | — |
| 2018-06-30 | $0.00B | +$0.00B | — |
| 2017-06-30 | $0.00B | +$0.00B | — |
| 2016-06-30 | $0.00B | +$0.00B | — |
| 2015-06-30 | $0.00B | +$0.00B | — |
| 2014-06-30 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Innovation Pharmaceuticals Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Innovation Pharmaceuticals Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Innovation Pharmaceuticals Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IPIX revenue · 4 questionsIPIX's trailing twelve-month (TTM) revenue is $-0.00B. That is a decrease of 100.00% year-over-year from $0.00B in FY2023.
▸ Source: FMP · Innovation Pharmaceuticals Inc. SEC filings · GAAP · Innovation Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026